Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HL217 Eye Drops in Healthy Male Subjects
NCT03650608Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of KR-31831 in neovascular age-related macular degeneration (NVAMD) (4 arms), sponsored by Hanlim Pharm. Primary endpoints: Adverse Events at 72 hours and Local Tolerance at 72 hours. Started Aug 2016; status: completed.
02
Drugs
KR-31831
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03650608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650608.